Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection.
clinical research/practice
infection and infectious agents - viral: Cytomegalovirus (CMV)
infectious disease
molecular biology
molecular biology: DNA
translational research/science
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
27
11
2020
received:
02
04
2020
accepted:
08
12
2020
pubmed:
16
12
2020
medline:
22
6
2021
entrez:
15
12
2020
Statut:
ppublish
Résumé
Letermovir (LMV) inhibits HCMV replication by binding to components of the HCMV-terminase complex showing a potential role in prevention of HCMV-related complications in allogenic hematopoietic stem cell transplant recipients (allo-HSCTRs). However, little is known about breakthrough HCMV infection and the relevance of HCMV DNAemia during prophylaxis. We reported the results of a multicenter prospective study involving five Italian centers in the management of HCMV DNAemia in 75 adult HCMV-seropositive allo-HSCTRs undergoing LMV prophylaxis. The aim of the present study was to characterize the presence of real HCMV reactivation during LMV prophylaxis. Then, the presence of circulating infectious HCMV particles was determined by virus isolation and degradation of free-floating viral DNA. This report provides the first evidence that during LMV prophylaxis the clinical relevance of HCMV DNAemia should be critically considered.
Identifiants
pubmed: 33320429
doi: 10.1111/ajt.16450
pii: S1600-6135(22)08510-0
doi:
Substances chimiques
Acetates
0
Antiviral Agents
0
DNA, Viral
0
Quinazolines
0
letermovir
1H09Y5WO1F
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1622-1628Informations de copyright
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Camargo JF, Kimble E, Rosa R, et al. Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24:806-814.
El Helou G, Razonable RR. Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation. Expert Opin Drug Saf. 2019;18:1017-1030.
Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complication of the late cytomegalovirus infection after allogenic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015;162(1):1-10.
Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med. 1991;324:1057-1059.
Girmenia C, Lazzarotto T, Bonifazi F, et al. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. Clin Transplant. 2019;33:e13666.
Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433-2444.
Chou S, Satterwhite LE, Ercolani RJ. New locus of drug resistance in the human Cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir. Antimicrob Agents Chemother. 2018;62:e00922-18.
Gentry BG, Bogner E, Drach JC. Targeting the terminase: an important step forward in the treatment and prophylaxis of human cytomegalovirus infections. Antiviral Res. 2019;161:116-124.
Razonable RR. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation. Curr Opin Infect Dis. 2018;31:286-291.
Furione M, Rognoni V, Cabano E, et al. Kinetics of human cytomegalovirus (HCMV) DNAemia in transplanted patients expressed in international units as determined with the Abbott RealTime CMV assay and an in-house assay. J Clin Virol. 2012;55:317-322.
Sidoti F, Piralla A, Costa C, et al. Collaborative national multicenter for the identification of conversion factors from copies/mL to international units/mL for the normalization of HCMV DNA load. Diagn Microbiol Infect Dis. 2019;95:152-158.
Revello MG, Percivalle E, Arbustini E, et al. In vitro generation of human cytomegalovirus pp65 antigenemia, viremia, and leukoDNAemia. J Clin Invest. 1998;101:2686-2692.
Gerna G, Sarasini A, Lilleri D, et al. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J Infect Dis. 2003;188:1639-1647.
Tong Y, Pang XL, Mabilangan C, et al. Determination of the biological form of human Cytomegalovirus DNA in the plasma of solid-organ transplant recipients. J Infect Dis. 2017;215:1094-1101.
Gerna G, Vitulo P, Rovida F, et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol. 2006;78:408-416.
Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85:10884-10893.
Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010;54:1290-1297.
Lazzarotto T, Chiereghin A, Piralla A, et al. Cytomegalovirus and Epstein-Barr virus DNA kinetics in whole blood and plasma of allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24:1699-1706.